iRhythm Technologies to Present at Three Major Healthcare Conferences in September 2025

iRhythm Technologies (IRTC) will present at three major healthcare conferences in September 2025, including Wells Fargo, Morgan Stanley, and Baird Global Healthcare Conferences. Webcasts of the presentations will be available on iRhythm's investor relations website. The company aims to provide insights into its disease detection and prediction capabilities.

iRhythm Technologies (NASDAQ: IRTC), a leading digital healthcare company focused on disease detection and prediction solutions, has announced its participation in three upcoming investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference on September 3 at 12:45 PM ET, the Morgan Stanley Global Healthcare Conference on September 9 at 2:35 PM ET, and the Baird Global Healthcare Conference on September 10 at 12:50 PM ET. Webcasts will be available on the company's investor relations website [1].

iRhythm Technologies specializes in creating trusted solutions that detect, prevent, and predict disease. The company combines wearable biosensors and cloud-based data analytics with proprietary algorithms to distill data from millions of heartbeats into clinically actionable information. Through its relentless focus on patient care, iRhythm aims to deliver better data, better insights, and better health for all [1].

The company's Zio System, which includes the Zio Monitor System, Zio XT System, and Zio AT System, offers ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry monitoring services. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data [2].

Recent studies have highlighted the clinical superiority of iRhythm's Zio LTCM service. The largest real-world study of its kind, with 428,707 patients, demonstrated that the Zio LTCM service outperformed other monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total healthcare costs. This study, published in the American Journal of Managed Care, builds on the CAMELOT study, which demonstrated the Zio LTCM service's value among a Medicare population [3].

At the upcoming conferences, iRhythm Technologies aims to provide insights into its disease detection and prediction capabilities, as well as the clinical benefits of its Zio LTCM service. The company's management team will present at each conference, and interested parties can access live and archived webcasts of the presentations on the “Events & Presentations” section of the company’s investor website [1].

References:
[1] https://www.stocktitan.net/news/IRTC/i-rhythm-technologies-to-participate-in-upcoming-investor-gncxooygvfpi.html
[2] https://www.marketscreener.com/news/spruce-point-issues-strong-sell-report-on-irhythm-technologies-ce7c51dcd88cf621
[3] https://www.nasdaq.com/press-release/avalon-real-world-evidence-builds-camelot-study-reinforcing-irhythms-zio-ltcm